Adaptin Bio (APTN) Research & Development (2024 - 2026)
Adaptin Bio (APTN) posted Research & Development of $165577.0 for Q1 2026, down 72.08% sequentially from $593035.0 in Q4 2025, and up 166.49% YoY from $62133.0 in Q1 2025.
Adaptin Bio (APTN) Research & Development (2024 - 2026) Analysis & Trends
Adaptin Bio has reported Research & Development for 3 years, with the latest figure at $165577.0 in Q1 2026.
- Quarterly Research & Development rose 166.49% year-over-year to $165577.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 11.25% YoY) and the FY2025 annual result came in at $1.8 million, down 2.76% from the prior year.
- Research & Development slipped to $165577.0 in Q1 2026 per APTN's latest filing, from $593035.0 in the prior quarter.
- Over five years, Research & Development peaked at $778664.0 in Q3 2025 and troughed at $62133.0 in Q1 2025.
- A 3-year average of $418259.3 and a median of $340334.0 in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2025 and 2026: Research & Development slumped 68.77% in 2025, then soared 166.49% in 2026.
- Over 3 years, Research & Development stood at $258058.0 in 2024, then soared by 129.81% to $593035.0 in 2025, then plunged by 72.08% to $165577.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $165577.0, $593035.0, and $778664.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138,167.00 |
| Mar 31, 2026 | 165,577.00 |
| Dec 31, 2025 | 593,035.00 |
| Sep 30, 2025 | 778,664.00 |
| Jun 30, 2025 | 340,334.00 |
| Mar 31, 2025 | 62,133.00 |
| Dec 31, 2024 | 258,058.00 |
| Sep 30, 2024 | 682,546.00 |
| Jun 30, 2024 | 685,028.00 |
| Mar 31, 2024 | 198,959.00 |